ALK4:ActRIIB Heterodimers for Selective TGF-Beta Ligand Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing TGF-beta superfamily ligands lack selective antagonists that can effectively promote anabolic effects on skeletal muscle and bone while minimizing catabolic effects on adipose tissue and avoiding interference with processes like angiogenesis.
Innovation Solution
Development of ALK4:ActRIIB heterodimer protein complexes that exhibit enhanced binding to activin B, activin A, and GDF11, while reducing binding to BMP9 and BMP10, providing selective antagonism of these ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ActRIIB homodimer is used as antagonist, then binding to BMP9 and BMP10 is strong, but this causes unwanted inhibition of angiogenesis and interference with normal physiological processes
Solution Approach 1:
The patent applies local quality by creating a heterodimeric receptor complex (ALK4:ActRIIB) where each subunit contributes different binding properties. The ActRIIB subunit provides binding capability for activins and GDFs, while the ALK4 subunit modifies the overall ligand specificity profile to reduce BMP9 and BMP10 binding. This localized functional differentiation within the complex achieves selective antagonism without broad-spectrum inhibition.
Solution Approach 2:
The invention employs asymmetry by designing an heterodimeric complex rather than a symmetric homodimer. The ALK4:ActRIIB heterodimer has asymmetric subunit composition that creates distinct binding characteristics compared to ActRIIB homodimer. This asymmetric structure enables differential ligand recognition, enhancing selectivity for activins and GDFs while reducing affinity for BMP9 and BMP10, thereby avoiding unwanted angiogenesis inhibition.
2Adaptability or versatility
If broad-spectrum TGF-beta ligand antagonism is achieved, then multiple tissue effects are observed, but this causes interference with normal physiological processes like angiogenesis
Solution Approach 1:
The ALK4:ActRIIB heterodimer achieves local quality by having different subunits contribute different binding specificities. The complex selectively antagonizes activins and GDFs (including GDF8/myostatin and GDF11) while exhibiting reduced binding to BMP9 and BMP10. This localized specificity allows versatile therapeutic effects on muscle, bone, and adipose tissue without broad interference with physiological processes like angiogenesis.
Solution Approach 2:
The patent applies parameter changes by modifying the receptor complex composition from ActRIIB homodimer to ALK4:ActRIIB heterodimer. This compositional change alters the binding parameters (affinity and specificity) for different TGF-beta ligands. The heterodimer maintains strong binding to activins and GDFs while reducing binding affinity for BMP9 and BMP10, thereby achieving selective antagonism with reduced off-target effects.
3Strength
If ActRIIB homodimer is used to antagonize activins and GDFs, then anabolic effects on muscle and bone are achieved, but catabolic effects on adipose tissue and other unwanted effects also occur
Solution Approach 1:
The ALK4:ActRIIB heterodimer applies local quality by creating a receptor complex with tailored binding properties. The complex maintains strong antagonism of activins and GDFs (including GDF8/myostatin) to preserve anabolic effects on muscle and bone, while the modified ligand specificity profile reduces antagonism of other ligands that mediate catabolic effects on adipose tissue. This localized functional optimization achieves desired therapeutic effects with reduced side effects.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4: ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4: ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.